丙戊酸和鋰鹽屬於情緒穩定劑，常用於躁鬱症的治療。丙戊酸和鋰鹽主要的副作用是引發病人代謝異常，但代謝異常發生與否常因人而異。本篇研究想探討和攝食行為及能量代謝有關的瘦素受體基因之單一位點核苷酸變異，是否與服用情緒穩定劑所引起的代謝異常有關。
由國立成功大學附設醫院招募117位符合DSM-IV診斷標準的躁鬱症病人，測量病人的代謝指標及定序由Hapmap project 網站上挑選之瘦素受體基因單一位點核苷酸變異。挑選之瘦素受體基因單一位點核苷酸變異之連結性不平衡和haplotypes則由Haploview程式分析。接著本研究利用SPSS軟體分析各代謝指標和瘦素受體基因單一位點核苷酸變異之基因型是否有關；最後則利用SPSS軟體分析代謝指標和血中藥物濃度之關聯性在特定瘦素受體單一位點核苷酸變異的三個基因型之間是否有顯著差異。
結果發現瘦素受體單一位點核苷酸變異 rs1327121、rs8179183及rs4655555各基因型之比例在病人與健康受試者間有顯著差異。而這三個位點所構成的haplotype AGT在健康受試者所占的比例顯著高於躁鬱症病人，表示相較於其它haplotype，AGT可能是和躁鬱症關聯性較小的基因標誌。接著發現瘦素受體單一位點核苷酸變異rs12145690、rs9436747和rs8179183之各基因型比例與特定代謝指標間有顯著的關聯性。這個結果暗示瘦素受體基因上的單一位點核苷酸變異和服用情緒穩定劑後之躁鬱症病患的代謝異常有關。最後則是發現代謝指標和血中丙戊酸濃度之關聯性在rs1327122及rs9436747的三個基因型之間有顯著差異。此結果暗示服用丙戊酸可能在不同瘦素受體基因型的病人中引起不同的代謝改變。
本篇研究的結果顯示瘦素受體基因之單一位點核苷酸變異與躁鬱症及服用情緒穩定劑所引起的代謝改變有關。

Valproic acid and lithium are mood stabilizers that were used for bipolar patients. The major side effect of valprioc acid and lithium is medication induced metabolic abnormalities. However, the effect is variable between individuals. In our study, we try to test whether single nucleotide polymorphisms (SNPs) of the leptin receptor (LEPR) gene that corresponding to feeding behavior and energy expenditure are associated with the metabolic abnormalities caused by mood stabilizers.
Subjects (n=117) meet the DSM-IV criteria for bipolar disorder were recruited from the National Cheng Kung University Hospital. Metabolic indexes were measured. Specific SNPs of the LEPR chosen from Hapmap project were genotyped. The linkage disequilibrium and haplotypes of the SNPs were first estimated by the Haploview program. Then we tested the possible associations between genetic variances and metabolic indexes analyzed by SPSS program.
Results showed the genotype frequencies of the rs1327121, rs8179183 and rs4655555 variances were significantly different between patients and control. Besides, the frequency of haplotype AGT composed of rs1327121, rs8179183 and rs4655555 were significantly higher in control than in the patient group. It suggested that people who own haplotype AGT might be protected from bipolar disorder.
Variances of the rs12145690, rs9436747 and rs8179183 were associated with metabolic indexes in patients, these variances might relate to the metabolic changes of bipolar patients taking mood stabilizers. The correlation between metabolic indexes and plasma valproate levels were significantly different among different rs1327121 and rs9436747 genotypes. These results indicated that valproate might induce different metabolic responses in different LEPR genotypes.
Our study indicated SNPs of LEPR gene were associated with bipolar disorder and metabolic changes induced by mood stabilizers.

Atmaca, M., M. Kuloglu, et al. (2002). "Weight gain and serum leptin levels in patients on lithium treatment." Neuropsychobiology 46(2): 67-9.

Binder, E. B. and F. Holsboer (2006). "Pharmacogenomics and antidepressant drugs." Ann Med 38(2): 82-94.

Chua, S. C., Jr., I. K. Koutras, et al. (1997). "Fine structure of the murine leptin receptor gene: splice site suppression is required to form two alternatively spliced transcripts." Genomics 45(2): 264-70.

Crawford, D. C. and D. A. Nickerson (2005). "Definition and clinical importance of haplotypes." Annu Rev Med 56: 303-20.

Du, J., N. A. Gray, et al. (2003). "Structurally dissimilar antimanic agents modulate synaptic plasticity by regulating AMPA glutamate receptor subunit GluR1 synaptic expression." Ann N Y Acad Sci 1003: 378-80.

Du, J., N. A. Gray, et al. (2004). "Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression." J Neurosci 24(29): 6578-89.

Fenkci, S., S. Rota, et al. (2006). "Relationship of serum interleukin-6 and tumor necrosis factor alpha levels with abdominal fat distribution evaluated by ultrasonography in overweight or obese postmenopausal women." J Investig Med 54(8): 455-60.

Fisher, R. S. and J. Ho (2002). "Potential new methods for antiepileptic drug delivery." CNS Drugs 16(9): 579-93.

Forabosco, P., M. Falchi, et al. (2005). "Statistical tools for linkage analysis and genetic association studies." Expert Rev Mol Diagn 5(5): 781-96.

Goddard, M. E. and B. J. Hayes (2007). "Genomic selection." J Anim Breed Genet 124(6): 323-30.

Guo, S. W. (1997). "Linkage disequilibrium measures for fine-scale mapping: a comparison." Hum Hered 47(6): 301-14.

Han, H., H. J. Ryu, et al. (2008). "Genetic variations in the leptin and leptin receptor genes are associated with type 2 diabetes mellitus and metabolic traits in the Korean female population." Clin Genet.

Harvey, J., N. Solovyova, et al. (2006). "Leptin and its role in hippocampal synaptic plasticity." Prog Lipid Res 45(5): 369-78.

Havel, P. J. (2001). "Peripheral signals conveying metabolic information to the brain: short-term and long-term regulation of food intake and energy homeostasis." Exp Biol Med (Maywood) 226(11): 963-77.

Hedrick PW (2000). "Measures of Genetic Variation. "

Hirschfeld, R. M. (2007). "Screening for bipolar disorder." Am J Manag Care 13(7 Suppl): S164-9.

Hotta, K. (2005). "[Genetic testing and gene-based testing for obesity]." Nippon Rinsho 63 Suppl 12: 280-4.

Houseknecht, K. L., C. A. Baile, et al. (1998). "The biology of leptin: a review." J Anim Sci 76(5): 1405-20.

Joy, T., P. Lahiry, et al. (2008). "Genetics of metabolic syndrome." Curr Diab Rep 8(2): 141-8.

Katz, D. A. (2006). "Overview of pharmacogenetics." Curr Protoc Hum Genet Chapter 9: Unit 9 19.

Kharrat, N., M. Rebai, et al. (2005). "[Linkage disequilibrium in the human genome and its exploitation]." Arch Inst Pasteur Tunis 82(1-4): 9-21.

Kilpelainen, T. O., T. A. Lakka, et al. (2008). "Interaction of single nucleotide polymorphisms in ADRB2, ADRB3, TNF, IL6, IGF1R, LIPC, LEPR, and GHRL with physical activity on the risk of type 2 diabetes mellitus and changes in characteristics of the metabolic syndrome: The Finnish Diabetes Prevention Study." Metabolism 57(3): 428-36.

Kirchheiner, J., K. Nickchen, et al. (2004). "Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response." Mol Psychiatry 9(5): 442-73.

Koo, S. H. and E. J. Lee (2006). "Pharmacogenetics approach to therapeutics." Clin Exp Pharmacol Physiol 33(5-6): 525-32.

Kunugi, H., M. Hattori, et al. (1997). "Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder." Mol Psychiatry 2(6): 457-62.

Kushner, R. F. and D. J. Blatner (2005). "Risk assessment of the overweight and obese patient." J Am Diet Assoc 105(5 Suppl 1): S53-62.

Lan, T. H., E. W. Loh, et al. (2008). "Performance of a neuro-fuzzy model in predicting weight changes of chronic schizophrenic patients exposed to antipsychotics." Br J Pharmacol.

Lerer, B. and F. Macciardi (2002). "Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions." Int J Neuropsychopharmacol 5(3): 255-75.

Lu, X. Y. (2007). "The leptin hypothesis of depression: a potential link between mood disorders and obesity?" Curr Opin Pharmacol 7(6): 648-52.

Maier, W., A. Zobel, et al. (2008). "Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response." Eur Arch Psychiatry Clin Neurosci 258 Suppl 1(5): 12-20.

McIntyre, R. S., D. A. Mancini, et al. (2003). "Valproate, bipolar disorder and polycystic ovarian syndrome." Bipolar Disord 5(1): 28-35.

Mulder, H., B. Franke, et al. (2007). "The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study." Pharmacogenomics J 7(5): 318-24.

Nousbeck, J., R. Spiegel, et al. (2008). "Alopecia, neurological defects, and endocrinopathy syndrome caused by decreased expression of RBM28, a nucleolar protein associated with ribosome biogenesis." Am J Hum Genet 82(5): 1114-21.

Rao, J. S., R. N. Ertley, et al. (2007). "Dietary n-3 PUFA deprivation alters expression of enzymes of the arachidonic and docosahexaenoic acid cascades in rat frontal cortex." Mol Psychiatry 12(2): 151-7.

Ruetsch, O., A. Viala, et al. (2005). "[Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management]." Encephale 31(4 Pt 1): 507-16.

Sasaki, M., M. Yuzawa, et al. (2007). "New HLA DRB1 and DQB1 haplotypes in a pedigree of familial Graves' disease in Japan." Endocr J 54(5): 721-5.

Schloesser, R. J., J. Huang, et al. (2008). "Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder." Neuropsychopharmacology 33(1): 110-33.

Summers, A. O. (2006). "Genetic linkage and horizontal gene transfer, the roots of the antibiotic multi-resistance problem." Anim Biotechnol 17(2): 125-35.

Takaya, K., Y. Ogawa, et al. (1996). "Molecular cloning of rat leptin receptor isoform complementary DNAs--identification of a missense mutation in Zucker fatty (fa/fa) rats." Biochem Biophys Res Commun 225(1): 75-83.

Trojnar, M. K., E. Wierzchowska-Cioch, et al. (2004). "New generation of valproic acid." Pol J Pharmacol 56(3): 283-8.

Verrotti, A., F. Basciani, et al. (1999). "Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid." Neurology 53(1): 230-2.

Zarate, C. A., Jr., J. Du, et al. (2003). "Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system." Ann N Y Acad Sci 1003: 273-91.

Zarkesh-Esfahani, H., G. Pockley, et al. (2001). "High-dose leptin activates human leukocytes via receptor expression on monocytes." J Immunol 167(8): 4593-9.

Zhang, F., Y. Chen, et al. (2005). "Leptin: structure, function and biology." Vitam Horm 71: 345-72.